Efficacy of a probiotic supplement in improving atopic dermatitis symptoms. A randomized double blind placebo controlled clinical trial

Complife Italia Srl0 个研究点目标入组 80 人开始时间: 2020年3月5日最近更新: 2021年8月24日

适应症

试验速览

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33871363/ (added 13/08/2021)

•1. Aged 18-50 years, with Phototype I to IV
•2. Mild to moderate SCORAD (between 15 and 25)
•3. Willingness to use during all the study period only the products to be tested
•4. Subjects who have not been recently involved in any other similar study
•5. Willingness to not use products likely to interfere with the products to be tested
•6. Willingness to not vary the normal daily routine (i.e. lifestyle, physical activity, etc.)

•1. Current antibiotic administration
•2. Known history of chronic medical condition such as congenital heart disease, liver or kidney disease, or immune deficiency
•3. Treatment with probiotics in the 6 months preceding enrollment
•4. Treatment with steroids and antihistamines systemically in the three months prior to enrollment
•5. Topical treatments with immunomodulators (tacrolimus or pimecrolimus) in the three months prior to enrollment
•6. Acute or chronic infectious diseases
•7. Subjects who has used sun-beds or self-tanning product for one month before the study or intend to use it during the present study

发起方